Cisplatin

Pricing Availability Delivery Time Qty
Cat.No. 2251 - Cisplatin | Cl2H6N2Pt | CAS No. 15663-27-1
Description: Potent pro-apoptotic anticancer agent; activates caspase-3
Alternative Names: CDDP
Chemical Name: cis-Diaminodichloroplatinum
Datasheet
Citations (19)
Reviews (1)
Literature

Biological Activity

Potent anticancer agent that blocks DNA synthesis. Induces apoptosis via p53-dependent and -independent mechanisms. Inhibits X-linked inhibitor of apoptosis protein (XIAP) expression and activates caspase-3. In certain glioma cell lines, sensitizes cells to TNF-α-induced apoptosis.

Technical Data

M. Wt 300.05
Formula Cl2H6N2Pt
Storage Store at RT
CAS Number 15663-27-1
PubChem ID 84691
InChI Key LXZZYRPGZAFOLE-UHFFFAOYSA-L
Smiles N.N.[Cl-].[Cl-].[Pt++]

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
water 1.5 5 with gentle warming

Preparing Stock Solutions

The following data is based on the product molecular weight 300.05. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.33 mL 16.66 mL 33.33 mL
5 mM 0.67 mL 3.33 mL 6.67 mL
10 mM 0.33 mL 1.67 mL 3.33 mL
50 mM 0.07 mL 0.33 mL 0.67 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:
Safety Datasheet

References

References are publications that support the biological activity of the product.

Seki et al (2000) Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma. Cancer Chemother.Pharmacol. 45 199 PMID: 10663637

Duan et al (2004) Impairment of both apoptotic and cytoprotective signalings in glioma cells resistant to the combined use of cisplatin and tumor necrosis factor α. Clin.Cancer Res. 10 234 PMID: 14734475

Nomura et al (2004) Cisplatin inhibits the expression of X-linked inhibitor of apoptosis protein in human LNCaP cells. Urol.Oncology 22 453


If you know of a relevant reference for Cisplatin, please let us know.

View Related Products by Target

View Related Products by Product Action

View all Caspase Activators

Keywords: Cisplatin, Cisplatin supplier, Potent, proapoptotic, anticancer, agent, activates, caspase-3, DNA-alkylating, antitumor, Caspases, Apoptosis, Inducers, Proteinases, Proteases, chemotherapeutics, CDDP, 2251, Tocris Bioscience

19 Citations for Cisplatin

Citations are publications that use Tocris products. Selected citations for Cisplatin include:

Szabova et al (2014) Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer. Cell Rep 9 e95649 PMID: 24748377

Chia et al (2017) Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time. Nat Commun 8 435 PMID: 28874669

Zhang (2017) The BTK Inhibitor, Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1 and ABCC10 Overexpressing Cells and Tumors. Mol Cancer Ther 16 1021 PMID: 28265007

Liu and Kwiatkowski (2015) Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target. Mol Cancer Ther 14 174 PMID: 25349305

Kathawala et al (2014) Masitinib antagonizes ATP-binding cassette subfamily C member 10-mediated paclitaxel resistance: a preclinical study. Mol Cancer Ther 13 714 PMID: 24431074

Kathawala et al (2014) Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. Int J Oncol 44 1634 PMID: 24626598

Guindon et al (2014) Optimization of a cisplatin model of chemotherapy-induced peripheral neuropathy in mice: use of vitamin C and sodium bicarbonate pretreatments to reduce nephrotoxicity and improve animal health status. Mol Pain 10 56 PMID: 25189223

Kim et al (2016) Identification of therapeutic targets applicable to clinical strategies in ovarian cancer. BMC Cancer 16 678 PMID: 27558154

Guindon et al (2013) Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following c Pharmacol Res 67 94 PMID: 23127915

Ibáñez et al (2012) A high throughput scintillation proximity imaging assay for protein methyltransferases. Comb Chem High Throughput Screen 15 359 PMID: 22256970

Natrajan et al (2012) Functional characterization of the 19q12 amplicon in grade III breast cancers. Breast Cancer Res 14 R53 PMID: 22433433

Kathawala et al (2015) The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study. Oncotarget 6 510 PMID: 25402202

Deng et al (2012) The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB? receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy. Mol Pain 8 71 PMID: 22998838

Marcus et al (2015) Tolerance to the antinociceptive effects of chronic morphine requires c-Jun N-terminal kinase. Mol Pain 11 34 PMID: 26065412

Robinson et al (2013) RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs. PLoS One 8 e78641 PMID: 24265703

Fard et al (2013) The heterogenic final cell cycle of chicken retinal Lim1 horizontal cells is not regulated by the DNA damage response pathway. Cell Cycle 13 408 PMID: 24247150

Saja et al (2015) Triglyceride-Rich Lipoproteins Modulate the Distribution and Extravasation of Ly6C/Gr1(low) Monocytes. Cell Death Dis 12 1802 PMID: 26344769

Sun et al (2015) SOX4 contributes to the progression of cervical cancer and the resistance to the chemotherapeutic drug through ABCG2. Korean J Pain 6 e1990 PMID: 26583330

Lin et al (2015) A New Rat Model of Cisplatin-induced Neuropathic Pain. Oncotarget 28 236 PMID: 26495078


Do you know of a great paper that uses Cisplatin from Tocris? Please let us know.

Reviews for Cisplatin

Average Rating: 5 (Based on 1 Review.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Cisplatin?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


dose response
By Anonymous on 05/01/2018
Assay Type: In Vitro
Species: Human
Cell Line/Tissue: H524

Determined the optimal dose to identify the chemoresistant population in our cell line. Cells were treated with escalating doses of cisplatin (0.01-100uM) and viability determined 4 days post treatment.

review image

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cancer

Cancer Research Product Guide

A collection of over 750 products for cancer research, the guide includes research tools for the study of:

  • Cancer Metabolism
  • Epigenetics in Cancer
  • Receptor Signaling
  • Cell Cycle and DNA Damage Repair
  • Angiogenesis
  • Invasion and Metastasis
Neurodegeneration

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
Cell Cycle & DNA Damage Repair

Cell Cycle & DNA Damage Repair Poster

In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.

Huntington's Disease

Huntington's Disease Poster

Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.

Programmed Cell Death

Programmed Cell Death Poster

There are two currently recognized forms of programmed cell death: apoptosis and necroptosis. This poster summarizes the signaling pathways involved in apoptosis, necroptosis and cell survival following death receptor activation, and highlights the influence of the molecular switch, cFLIP, on cell fate.